Literature DB >> 1679880

Ondansetron.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1679880

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement.

Authors:  Lawrence H Einhorn; Bernardo Rapoport; Jim Koeller; Steven M Grunberg; Petra Feyer; Cynthia Rittenberg; Matti Aapro
Journal:  Support Care Cancer       Date:  2004-10-09       Impact factor: 3.603

Review 2.  Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.

Authors:  G L Plosker; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

Review 3.  Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.

Authors:  Anthony Markham; Eugene M Sorkin
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 4.  Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.

Authors:  P J Hesketh
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.